Alcoholic Hepatitis Market

 Market Overview:

The 7 major alcoholic hepatitis markets reached a value of US$ 1.9 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3.1 Billion by 2034, exhibiting a growth rate (CAGR) of 4.37% during 2024-2034.

The alcoholic hepatitis market has been comprehensively analyzed in IMARC's new report titled "Alcoholic Hepatitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Alcoholic hepatitis is a liver disease that occurs as a result of long-term excessive alcohol consumption. The condition is characterized by inflammation and damage to the liver, which can cause a range of symptoms, including jaundice, abdominal pain and swelling, fever, nausea and vomiting, fatigue, loss of appetite, etc. In some cases, people with alcoholic hepatitis may also experience confusion, agitation, and other signs of alcohol withdrawal, such as tremors, seizures, delirium tremens, etc. The diagnosis of alcoholic hepatitis typically involves a combination of medical history, physical examination, laboratory examinations, and imaging studies. Blood tests can help identify liver damage and inflammation, as well as other conditions that may be contributing to the symptoms. Several imaging studies, including ultrasound, CT scans, MRI scans, etc., can provide detailed images of the liver and aid in revealing any abnormalities. In some cases, a liver biopsy may be necessary to confirm the diagnosis and guide treatment decisions.

The increasing prevalence of liver diseases on account of rising alcohol consumption is primarily driving the alcoholic hepatitis market. Besides this, the escalating utilization of corticosteroids, such as prednisolone and pentoxifylline, for reducing inflammation and improving liver function in severe cases of alcoholic hepatitis is further creating a positive outlook for the market. Moreover, the emerging popularity of non-invasive tests, including elastography and magnetic resonance imaging (MRI), for monitoring liver function and disease progression is also bolstering the market growth. Additionally, several government bodies are introducing treatment and support programs, such as counseling and medication-assisted treatment, for people with alcohol use disorders, including those who have developed alcoholic hepatitis. This, in turn, is acting as another significant growth-inducing factor. Furthermore, the widespread adoption of transjugular intrahepatic portosystemic shunt (TIPS) procedure to treat complications related to alcoholic hepatitis, such as portal hypertension, is also propelling the market growth. Apart from this, numerous key players are making extensive investments in exploring novel treatments for alcoholic hepatitis, including stem cell therapy that involves transplanting stem cells into the liver to promote regeneration, which is expected to drive the alcoholic hepatitis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the alcoholic hepatitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for alcoholic hepatitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the alcoholic hepatitis market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the alcoholic hepatitis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the alcoholic hepatitis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current alcoholic hepatitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the alcoholic hepatitis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the alcoholic hepatitis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the alcoholic hepatitis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of alcoholic hepatitis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of alcoholic hepatitis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of alcoholic hepatitis by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with alcoholic hepatitis across the seven major markets?
• What is the size of the alcoholic hepatitis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of alcoholic hepatitis?
• What will be the growth rate of patients across the seven major markets?
   

Alcoholic hepatitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for alcoholic hepatitis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the alcoholic hepatitis market?
• What are the key regulatory events related to the alcoholic hepatitis market?
• What is the structure of clinical trial landscape by status related to the alcoholic hepatitis market?
• What is the structure of clinical trial landscape by phase related to the alcoholic hepatitis market?
• What is the structure of clinical trial landscape by route of administration related to the alcoholic hepatitis market?